… explored survival outcomes for > 47,000 breast cancer patients with de novo metastatic …
While our analysis demonstrated the expected improvements in survival, it is noteworthy that the …

… free survival and marginally prolonged overall survival among postmenopausal patients with
hormone receptor–positive metastatic breast cancer … We now report final survival outcomes. …

… -free survival as first- or second-line therapy for hormone receptor-positive (HR+)/HER2-negative
metastatic breast cancer prognosis. Given the recent publication of overall survival (OS…

… analyzed the clinicopathological characteristics and survival of de novo metastatic breast
cancer according to metastatic sites using the SEER data. Metastatic breast cancer (MBC) is …

… previously treated patients with metastatic HER2 + breast cancer. Survival has improved
based … status in terms of survival and sites of metastasis in metastatic breast cancer. This study …

… of metastatic disease has been less convincingly demonstrated. We have studied survival
data of patients with metastatic breast cancer (MBC) from a large academic cancer center over …

… More than 90% of breast cancers are not metastatic at the … Metastatic breast cancer is
treated according to subtype, with … overall survival for metastatic triple-negative breast cancer is …

… a full picture of the real-life overall survival (OS) of women diagnosed with metastatic
breast … contemporary observational database of patients with metastatic breast cancer (MBC). …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been … These guidelines are based on breast cancer (BC) biological subtypes even though …

… Among the patients with brain metastases, progression-free survival at 1 year was 24.9%
in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, …